

Patient Health Summary

Name: Ms Julie-Anne Broughton
Address: 4/28 Richmond Street
East Geelong 3219
D.O.B.: 30/10/1969
Record No.:
Home Phone:
Work Phone:
Mobile Phone: 0476540075

Gateway Plaza Family Medical Practice
641-659 Bellarine Hwy
Leopold 3224
03 52504566

Printed on 18th June 2024

Allergies/Adverse reactions:

Nil known.

Current Medications:

Epilim EC 200mg Enteric coated tablet	500mg Twice a day after meals As directed.
Kliovance 1mg;500mcg Tablet	1 Tablet Daily As directed.
Lipitor 20mg Tablet	1 Tablet Daily with meals.
Risperdal 2mg Tablet	1 Tablet In the evening As directed.
Risperdal 4mg Tablet	1 Tablet In the evening As directed.
Ventolin CFC-Free with counter 100mcg/dose Inhaler	2 puffs as needed.

Active Past History:

2000	Schizoaffective disorder
2014	Epilepsy
30/08/2021	Vertigo
25/09/2021	Migraine
27/02/2024	Schizophrenia

Inactive Past History:

Not recorded.

Immunisations:

30/04/2021	Vaxigrip Tetra (Influenza)
10/06/2021	COVID 19 Vaccine AstraZeneca (COVID-19)
03/09/2021	AstraZeneca VAXZEVRIA (COVID-19)
12/01/2022	Pfizer Comirnaty (COVID-19)
26/05/2022	Vaxigrip Tetra (Influenza)
08/11/2022	Spikevax Bivalent (COVID-19)
10/05/2023	Vaxigrip Tetra (Influenza)

04/12/2023 Pfizer Comirnaty Biv BA.4-5 (COVID-19)
18/06/2024 Vaxigrip Tetra (Influenza)

Investigations:

LESLIE, JULIE-ANNE
4/28 RICHMOND STREET, EAST GEELONG. 3219
Phone: 0476540075
Birthdate: 30/10/1969 **Sex:** F **Medicare Number:** 32366622031
Your Reference: 00117539 **Lab Reference:** 22-66903850-TSH-0
Laboratory: AUSTRALIAN CLINICAL LABS
Addressee: DR EMMANUEL NNOPU **Referred by:** DR EMMANUEL NNOPU

Name of Test: THYROID STIMULATING HORM
Requested: 17/08/2022 **Collected:** 17/08/2022 **Reported:** 17/08/2022 19:28

CLINICAL NOTES: chest pain FI

ENDOCRINOLOGY

THYROID FUNCTION TEST

SPECIMEN: SERUM

Date:	12/08/20	22/07/21	17/08/22
Time:	10:30	09:55	14:14
Lab Number:	43914182	53137892	66903850

Free T4				pmol/L
TSH	1.20	2.16	1.38 (0.40 - 4.00)	mIU/L

66903850 Normal TSH level.

ECG-C HAE-R CRP-C GLS-C GHB-W TSH-C TIH-W CK-C FBE-R ECU-V

This request has other tests in progress at the time of reporting

BROUGHTON, JULIE-ANNE
4/28 RICHMOND ST, EAST GEELONG. 3219
Phone: 0476540075
Birthdate: 30/10/1969 **Sex:** F **Medicare Number:** 32366622041
Your Reference: 00121242 **Lab Reference:** 23-75505744-OHD-0
Laboratory: AUSTRALIAN CLINICAL LABS
Addressee: DR EMMANUEL NNOPU **Referred by:** DR EMMANUEL NNOPU

Name of Test: VITAMIN D
Requested: 07/03/2023 **Collected:** 08/03/2023 **Reported:** 09/03/2023 06:08

CLINICAL NOTES: both legs and feet and hand numbness and pins

BIOCHEMISTRY

VITAMIN D

SPECIMEN: SERUM

Date	Req. No.	25-hydroxy Vitamin D	
08/03/23	75505744	104	nmol/L

75505744 Within normal limits.

Interpretation:

Vitamin D deficiency <50 nmol/L
Severe deficiency <20 nmol/L

COMMENT: Vitamin D sufficiency is defined as greater than or equal to 50 nmol/L at the end of winter (level may need to be 10-20 nmol/L higher at the end of summer).

Reference: Position Statement. Vitamin D and Health in Adults in Australia and New Zealand. MJA,196(11): 686-687, 2012.

This request has other tests in progress at the time of reporting

BROUGHTON, JULIE-ANNE

4/28 RICHMOND STREET, EAST GEELONG. 3219

Phone: 0476540075

Birthdate: 30/10/1969 Sex: F Medicare Number: 32366622041

Your Reference: 00126390 Lab Reference: 23-83658814-GLS-0

Laboratory: AUSTRALIAN CLINICAL LABS

Addressee: DR SANTOSH KURIEN Referred by: DR SANTOSH KURIEN

Name of Test: GLUCOSE

Requested: 06/12/2023 Collected: 12/12/2023 Reported: 13/12/2023 02:44

CLINICAL NOTES: cvd risk assessment

BIOCHEMISTRY

GLUCOSE

Date	Time	Lab#	Collection Type	Specimen	Glucose (mmol/L)
22/07/21	09:55	53137892	Fasting	serum	4.7
17/08/22	14:14	66903850	Random	serum	4.9
08/03/23	08:55	75505744	Fasting	serum	5.0
12/12/23	09:40	83658814	Fasting	serum	5.3

83658814 Normal fasting glucose.

NOTE: HbA1c has been requested.

Glucose Reference Ranges

Random 3.0 - 6.9 mmol/L

Fasting 3.0 - 5.4 mmol/L

1 Hour post prandial 3.0 - 11.0 mmol/L

2 Hour post prandial 3.0 - 7.7 mmol/L

Specimen Legend:

Fl-ox = Fluoride oxalate, serum = Serum, np = Non-Preserved

ECG-W GLS-C GHB-W FBE-R LIP-C ECU-V LFT-V

This request has other tests in progress at the time of reporting

BROUGHTON, JULIE-ANNE

4/28 RICHMOND STREET, EAST GEELONG. 3219

Phone: 0476540075

Birthdate: 30/10/1969 Sex: F Medicare Number: 32366622041

Your Reference: 00126390 Lab Reference: 23-83658814-LS-0

Laboratory: AUSTRALIAN CLINICAL LABS

Addressee: DR SANTOSH KURIEN Referred by: DR SANTOSH KURIEN

Name of Test: LIPID STUDIES

Requested: 06/12/2023 Collected: 12/12/2023 Reported: 13/12/2023 02:44

CLINICAL NOTES: cvd risk assessment

BIOCHEMISTRY

LIPID STUDIES

SPECIMEN: SERUM

Date:	09/03/22	08/03/23	12/12/23		
Coll Time:	09:00	08:55	09:40	Desirable Range	
Lab Number:	61430792	75505744	83658814	(Fasting)	
Fasting status	Fasting	Fasting	Fasting		
Total Chol.	* 5.9	* 6.8	4.2	(< 5.6)	mmol/L
HDL Chol.	1.3	1.4	* 1.1	(> 1.1)	mmol/L
LDL Chol.	* 3.6	* 4.2	2.1	(< 3.1)	mmol/L
Non-HDL Chol.	* 4.6	* 5.4	3.1	(< 4.1)	mmol/L
Triglyceride	* 2.2	* 2.6	* 2.2	(< 2.1)	mmol/L

LDL/HDL Ratio	2.8	3.0	1.9
Chol/HDL Ratio	4.5	4.9	3.8

83658814 Mild hypertriglyceridemia and borderline HDL cholesterol. Interpret in conjunction with other cardiovascular risk factors or treatment targets.

Please note, from 27/09/2023, modified lipid reference ranges apply.

Recommended targets for high risk patients are

Total cholesterol	< 4.0 mmol/L
HDL Cholesterol	> 1.0 mmol/L
LDL Cholesterol	< 2.5 mmol/L (< 1.8 mmol/L for very high risk)
Non-HDL Cholesterol	< 3.3 mmol/L (< 2.5 mmol/L for very high risk)
Fasting triglycerides	< 2.0 mmol/L

Lipid ranges and targets are from the AACB Guideline for Harmonised Lipid Reporting (2018)

Target values need to be individualised based on clinical assessment of overall risk.

See the AusCVD Risk calculator at www.cvdcheck.org.au

ECG-W GLS-C GHB-W FBE-R LIP-C ECU-V LFT-V

This request has other tests in progress at the time of reporting

BROUGHTON, JULIE-ANNE

4/28 RICHMOND STREET, EAST GEELONG. 3219

Phone: 0476540075

Birthdate: 30/10/1969 Sex: F Medicare Number: 32366622041

Your Reference: 00126390 Lab Reference: 23-83658814-GHB-0

Laboratory: AUSTRALIAN CLINICAL LABS

Addressee: DR SANTOSH KURIEN Referred by: DR SANTOSH KURIEN

Name of Test: GLYCATED HB

Requested: 06/12/2023 Collected: 12/12/2023 Reported: 13/12/2023 18:28

CLINICAL NOTES: cvd risk assessment

BIOCHEMISTRY

HAEMOGLOBIN A1c

SPECIMEN: WHOLE BLOOD

Date	Coll Time	Req. No.	IFCC HbA1c (mmol/mol)	DCCT HbA1c (%)
17/08/22	14:14	66903850	39	5.7
08/03/23	08:55	75505744	40	5.8
12/12/23	09:40	83658814	44	6.2

83658814 HbA1c in the range of 6.0 - 6.4% is consistent with prediabetes.

INTERPRETATION CRITERIA

DIAGNOSIS.

A HbA1c greater than or equal to 48 mmol/mol (6.5 %) is consistent with diabetes. Consider OGTT or repeat HbA1c for confirmation.

HbA1c 6.0 - 6.4% is consistent with prediabetes. Repeat testing annually is recommended. (ADS position statement 2020)

MONITORING.

The Australian Diabetes Society (ADS) recommends individualised HbA1c targets depending on the patient's age, comorbidities and any Hypoglycaemia (ADS position statement 2009).

A general target of less than or equal to 53 mmol/mol (7.0%) is often used.

Please note that Hb A1c results may be influenced by conditions affecting red cells or their survival times such as haemoglobinopathies, anaemias, recent transfusion or blood loss.

HbA1c tested on Roche c513 using Gen. 3 assay.

ECG-R GLS-R GHB-C FBE-R LIP-R ECU-R LFT-R

All tests on this request have now been completed